Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02892123
Recruitment Status : Recruiting
First Posted : September 8, 2016
Last Update Posted : August 4, 2021
Sponsor:
Information provided by (Responsible Party):
Zymeworks Inc.

Tracking Information
First Submitted Date  ICMJE August 23, 2016
First Posted Date  ICMJE September 8, 2016
Last Update Posted Date August 4, 2021
Study Start Date  ICMJE September 2016
Estimated Primary Completion Date January 31, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 18, 2019)
  • The proportion of patients who experience dose-limiting toxicities (DLTs) (Part 1) [ Time Frame: Up to 8 months ]
  • The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Parts 2 and 3) [ Time Frame: Throughout the duration of the study; up to 2 years ]
Original Primary Outcome Measures  ICMJE
 (submitted: September 1, 2016)
  • The proportion of patients experiencing dose limiting toxicities [ Time Frame: Up to 8 months (Part 1) ]
  • The proportion of patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment [ Time Frame: Throughout the duration of the study (Parts 1 and 2); up to 2 years ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 18, 2019)
  • Serum concentrations of ZW25 [ Time Frame: Throughout the duration of the study; up to 2 years ]
  • The proportion of patients who develop detectable anti-drug antibodies [ Time Frame: Throughout the duration of the study; up to 2 years ]
  • The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria [ Time Frame: Throughout the duration of the study; up to 2 years ]
  • Progression free survival as defined by RECIST 1.1 criteria [ Time Frame: Throughout the duration of the study; up to 2 years ]
  • The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Part 1) [ Time Frame: Throughout the duration of the study; up to 2 years ]
Original Secondary Outcome Measures  ICMJE
 (submitted: September 1, 2016)
  • Serum concentrations of ZW25 [ Time Frame: Throughout the duration of the study (Parts 1 and 2); up to 2 years ]
  • The proportion of patients who develop detectable anti-drug antibodies [ Time Frame: Throughout the duration of the study (Parts 1 and 2); up to 2 years ]
  • The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria [ Time Frame: Throughout the duration of the study (Parts 1 and 2); up to 2 years ]
  • Progression free survival as defined by RECIST 1.1 criteria [ Time Frame: Throughout the duration of the study (Parts 1 and 2); up to 2 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Official Title  ICMJE Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Brief Summary This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
Detailed Description

Part 1 of the study will evaluate increasing doses of ZW25 to find the highest dose of ZW25 that does not cause unacceptable side effects (maximum-tolerated dose or MTD), the lowest safe dose with the highest rate of effectiveness (optimal biological dose or OBD), and/or other recommended dosages (RDs) of ZW25 in up to 7 dose-specific cohorts. Eligible patients include those with selected HER2-expressing locally advanced (unresectable) and/or metastatic cancers that have progressed after receipt of all therapies known to confer clinical benefit (or ineligible to receive therapy).

Part 2 of the study will further evaluate the safety, tolerability, and efficacy of ZW25 in patients with selected HER2-expressing locally advanced (unresectable) and/or metastatic cancers that have progressed after receipt of all therapies known to confer clinical benefit (or ineligible to receive therapy) in up to 5 separate disease-specific cohorts.

Part 3 of the study will evaluate the safety, tolerability, and efficacy of ZW25 combined with selected chemotherapy agents, including paclitaxel, capecitabine, vinorelbine, or capecitabine and tucatinib. Patients with selected HER2-expressing locally advanced (unresectable) and/or metastatic cancers that have progressed after at least 1 and no more than 3 prior systemic chemotherapy regimens will be evaluated in this part of the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HER2-expressing Cancers
Intervention  ICMJE
  • Drug: ZW25 (Zanidatamab)
    ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
  • Drug: Paclitaxel
    Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
  • Drug: Capecitabine
    Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
  • Drug: Vinorelbine
    Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
  • Drug: Tucatinib
    Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
  • Drug: Tucatinib
    Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
Study Arms  ICMJE Experimental: ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy
Interventions:
  • Drug: ZW25 (Zanidatamab)
  • Drug: Paclitaxel
  • Drug: Capecitabine
  • Drug: Vinorelbine
  • Drug: Tucatinib
  • Drug: Tucatinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 28, 2021)
418
Original Estimated Enrollment  ICMJE
 (submitted: September 1, 2016)
30
Estimated Study Completion Date  ICMJE March 31, 2022
Estimated Primary Completion Date January 31, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. HER2-expressing cancer as follows:

    Part 1:

    • Cohorts 1 - 3: Any locally advanced (unresectable) and/or metastatic HER2-expressing (HER2 1+, 2+, or 3+ by IHC) cancer (including but not limited to breast, gastric, ovarian, colorectal and non-small cell lung) that has progressed after receipt of all therapies known to confer clinical benefit
    • Cohort 4:

      • HER2 IHC 2+ /FISH- breast cancer or gastroesophageal adenocarcinoma (GEA)
      • HER2 IHC 3+ or HER2 IHC 2+ /FISH+ breast cancer or GEA
      • Any other HER2 IHC 3+ or FISH+ cancer

        • HER2-overexpressing (3+ by IHC) or HER2-2+ and FISH+ breast cancer must have progressed after prior treatment with trastuzumab, pertuzumab, and T-DM1
        • HER2-overexpressing (3+ by IHC) or HER2-2+ and FISH+ GEA must have progressed after prior treatment with trastuzumab
        • Patients with colorectal cancer must be KRAS wild-type
        • Patients with NSCLC must have ALK wild-type, EGFR wild-type, and ROS1 fusion negative as determined by standard methods
    • Cohorts 5 - 6: HER2 IHC 3+ or HER2 IHC 2+ /FISH+ GEA must have progressed after prior treatment with trastuzumab
    • Cohort 7 (only at selected sites): HER2 IHC 3+, HER2 IHC 2+ /FISH+, or HER2 IHC 2+ /FISH- breast cancer must have progressed after prior treatment with trastuzumab, pertuzumab, and T-DM1

    Part 2:

    Locally advanced (unresectable) and/or metastatic cancer that has progressed after receipt of all therapies known to confer clinical benefit (unless ineligible to receive a specific therapy) as follows:

    • Cohort 1: HER2 IHC 2+/FISH- breast cancer
    • Cohort 2: HER2 IHC 3+ or HER2 IHC 2+/FISH+ breast cancer
    • Cohort 3: HER2 IHC 2+/FISH- GEA
    • Cohort 4: HER2 IHC 3+ or HER2 IHC 2+/FISH+ GEA
    • Cohort 5: Any other HER2 IHC 3+ or IHC 2+/FISH+ cancer, including the following:

      • Cohort 5a: HER2 IHC 3+ or IHC 2+/FISH+ GI cancers other than GEA (patients with colorectal cancer must be KRAS wild-type.)
      • Cohort 5b: Any other HER2 IHC 3+ or IHC 2+/FISH+ solid tumor types that are not breast or GI cancers (patients with NSCLC must have ALK wild-type, EGFR wild-type, and ROS1 fusion negative as determined by standard methods; patients with ovarian cancers must be KRAS wild type.)

    Part 3:

    Locally advanced (unresectable) and/or metastatic cancer as follows:

    • HER2 IHC 1+ or IHC2+/FISH- breast cancer patients (TGs 1, 2, or 3) who have received at least 1 and no more than 3 prior systemic chemotherapy regimens
    • HER2 IHC 3+ or IHC 2+/FISH+ breast cancer patients (TGs 1, 2, or 3) who have received prior therapy with trastuzumab, pertuzumab, and T-DM1, at least 1 and no more than 3 prior systemic chemotherapy regimens
    • HER2 IHC 2+ or 3+ FISH+ or FISH- GEA patients (TGs 1 or 2) who have received at least 1 and no more than 3 prior systemic chemotherapy regimens
    • HER2 IHC 3+ or IHC 2+/FISH+ GEA patients who have received prior therapy with trastuzumab (TG4; ZW25 + paclitaxel)
    • HER2 IHC 3+, IHC 2+/FISH+ or otherwise HER2-positive per ASCO/CAP guidelines breast cancer patients who have received prior therapy with trastuzumab, pertuzumab, and T-DM1 (TG5; ZW25 + capecitabine)
    • HER2 IHC 3+, IHC 2+/FISH+ or otherwise HER2-positive per ASCO/CAP guidelines breast cancer patients (TG6) who have received prior therapy with trastuzumab, pertuzumab, and T-DM1
    • HER2 IHC 3+, IHC2+/FISH+, or otherwise HER2-positive per ASCO/CAP guidelines breast cancer patients (TG7) who have received prior therapy with trastuzumab, pertuzumab, and T-DM1
    • HER2 IHC 3+, IHC 2+/FISH+, or otherwise HER2-positive per ASCO/CAP guidelines breast cancer patients (TG8) who have received prior therapy with trastuzumab, pertuzumab, and T-DM1
  2. ≥ 18 years of age
  3. ECOG performance status of 0 or 1
  4. Life expectancy of at least 3 months per the investigator's assessment.
  5. Adequate organ function
  6. Adequate cardiac left ventricular function, as defined by a LVEF >/= institutional standard of normal
  7. For Part 1 Cohorts 1 - 3: evaluable disease (target or non-target lesions) per RECIST version 1.1. For Part 1 Cohorts 4 - 7, and Parts 2 and 3: measurable disease (target lesions) per RECIST version 1.1
  8. Able to provide tumor sample (fresh or archived)
  9. For Part 3 TGs 7 and 8 only - based on screening brain MRI, patients must have one of the following:

    • No evidence of brain metastases
    • Untreated brain metastases not needing immediate local therapy. For patients with untreated CNS lesions > 2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment
    • Previously treated brain metastases that are either stable since treatment or have progressed since prior local CNS therapy, provided there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator

Exclusion Criteria:

  1. Experimental therapies within 4 weeks before first ZW25 dosing
  2. Treatment with other cancer therapy not otherwise specified within 4 weeks before ZW25 dosing
  3. Anthracyclines within 90 days before first ZW25 dosing or lifetime load exceeding 300 mg/m² adriamycin or equivalent
  4. Trastuzumab, pertuzumab, lapatinib, or T-DM1 within 3 weeks before first ZW25 dosing
  5. Patients in Part 3 TG4 must not have received prior taxanes
  6. Patients in Part 3 TG5 must not have received prior capecitabine for metastatic disease or received any prior fam-trastuzumab deruxtecan-nxki (DS-8201a)
  7. With the exception of Part 3 TGs 7 and 8, untreated brain metastases (patients with treated brain mets who are off steroids and are stable for at least 1 month at the time of screening are eligible)
  8. Pregnant or breast-feeding women
  9. History of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulation
  10. Acute or chronic uncontrolled renal disease, pancreatitis or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment)
  11. Peripheral neuropathy > Grade 2
  12. Clinically significant interstitial lung disease
  13. Known active hepatitis B or C or known infection with HIV
  14. Immunosuppressive corticosteroids equivalent to > 15mg/day of prednisone within 2 weeks before first ZW25 dose
  15. QTc Fridericia (QTcF) > 450 ms
  16. Having clinically significant cardiac disease such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic CHF
  17. Having known myocardial infarction or unstable angina within 6 months before first ZW25 dosing
  18. Patients in Part 3 TG7 must not have received prior capecitabine or tucatinib for metastatic disease
  19. Patients in Part 3 TG8 must not have received prior tucatinib therapy for metastatic disease
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Zymeworks Clinical Trial Resource (206) 237-1030 medinfo@zymeworks.com
Listed Location Countries  ICMJE Canada,   Korea, Republic of,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02892123
Other Study ID Numbers  ICMJE ZWI-ZW25-101
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Zymeworks Inc.
Study Sponsor  ICMJE Zymeworks Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Rajen Oza, MD, MBA Zymeworks Inc.
PRS Account Zymeworks Inc.
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP